In his article in the BMJ, “Psychiatry in crisis? Dr. Richard Smith, former editor of the BMJ (British Medical Journal) summarizes the message delivered by several speakers at a meeting also convened in June 2016. This meeting took place in Leiden, the . . . Continue reading →
I am here in vigorous opposition to SF 2841 that would implement mental health screening for three-year-old children entering public school. Continue reading →
The following announcement was posted on TeenScreen’s website (November 15, 2012): "Important Announcement for Schools & Communities: We are sorry to inform you that the TeenScreen National Center will be winding down its program at the end of this year. Accordingly, . . . Continue reading →
"From the start, the [Tri-University Schizophrenia Practice Guidelines] project subverted scientific integrity, appearing to be a purely scientific venture when it was at its core, a marketing venture for Risperdal."
"When you’re selling $1 billion a year or more of a drug, it’s very tempting for a company to just ignore the traffic ticket and keep speeding.” Continue reading →
The US government is initiating several radical medical experiments that will ensure widespread, increased use of mostly toxic drugs whose adverse effects trigger chronic, debilitating illnesses.
AHRP proposes a multi-disciplinary team of independent scientists to review ALL of Dr. Joseph Biederman’s publications and supporting documents, including: research protocols, consent forms, and the original (of course, anonymized) data sets with associated code books for all pediatric studies. Continue reading →
Pharmaceutical companies willingly settle court cases for hundreds of millions of dollars–even billions of dollars–to keep the truth about their drugs under seal. Continue reading →
“Bitter Pill” by Ben Wallace-Wells in the current issue of Rolling Stone is an excellent, informative, in-depth article providing an overview into the pharmaceutical industry’s immensely successful—albeit illegal—aggressive marketing tactics, for selling a particularly unsafe, dangerous class of drugs—the antipsychotics, Zyprexa in particular.
Continue reading →
This has the potential for restoring integrity to medicine by providing doctors and the public with impartial risk / benefit information about existing treatments devoid of commercial bias.
Continue reading →
A follow-up letter to FDA Commissioner, Andrew vonEschenbach RE: Thomas Laughren, FDA’s ‘s Director of Psychiatry Products who has been actively promoting psychotropic drugs–even penning his name to ghostwritten industry-sponsored articles and consensus panels. Continue reading →
No Free Lunch is an example of disingenuous focus on trivia while avoiding the real issues that are corrupting medicine. Continue reading →